Question from Deputy Ken O'Flynn - PQ 10654-26
Deputy O'Flynn asked whether the HSE has completed a formal evaluation for tirzepatide (mounjaro) and semaglutide (wegovy) for obesity or weight management.
From: Communications and public affairs
Published: February 2026
Updated: February 2026
Documents
Summary
To ask the Minister for Health whether the Health Service Executive has completed, or is in the process of completing, any National Centre for Pharmacoeconomics Rapid Review, Health Technology Assessment, or other formal evaluation for tirzepatide (mounjaro) and semaglutide (wegovy) for obesity or weight management; the date on which each assessment commenced; the current stage reached in each case; and the expected month in 2026 in which a pricing and reimbursement decision will be brought to the HSE senior leadership team.
This is a beta version - your feedback will help us to improve it